A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)

Plain-language summary

This study evaluates the drug Tarceva (Erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer. It included patients over 18 with measurable disease and no prior EGFR-targeted therapy. It was a Phase 2 study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Completed

Sponsor

Hoffmann-La Roche

Intervention

erlotinib

Start date

3/31/2011

Estimated completion

1/31/2017

Countries

Italy

Related genes

Locations

• Naples, Italy
• Bologna, Italy
• Modena, Italy
• Rome, Italy
• Milan, Italy
• Rozzano, Italy
• Catania, Italy
• Palermo, Italy
• Pisa, Italy
• Perugia, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Adult patients, \>/=18 years of age
* Locally advanced or metastatic non-small cell lung cancer
* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Life expectancy over \>/=12 weeks
* Adequate hematological, liver, or kidney function

Exclusion Criteria:

* Previous therapy against epidermal growth factor receptor for metastatic disease
* Treatment with investigational drug during the 3 weeks before enrollment
* History of neoplasm
* Patients with symptomatic cerebral metastases
* Unstable systemic disease